Everything below concerns PPARδ agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
== External links == GeneReviews/NCBI/NIH/UW entry on Epimerase Deficiency Galactosemia OMIM entries on Epimerase Deficiency Galactosemia UDPgalactose+4-Epimerase at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Attempts to reunite the Polish lands gained momentum in the 13th century, and in 1295, Duke Przemysł II of Greater Poland managed to become the first ruler since Bolesław II to be crowned king of Poland. He ruled over a limited territory and was soon killed. In 1300–1305 King Wenceslaus II of Bohemia also reigned as king of Poland. The Piast Kingdom was effectively restored under Władysław I the Elbow-high (r. 1306–1333), who became king in 1320. In 1308, the Teutonic Knights seized Gdańsk and the surrounding region of Pomerelia. King Casimir III the Great (r. 1333–1370), Władysław's son and the last of the Piast rulers, strengthened and expanded the restored Kingdom of Poland, but the western provinces of Silesia (formally ceded by Casimir in 1339) and most of Polish Pomerania were lost to the Polish state for centuries to come. Progress was made in the recovery of the separately governed central province of Mazovia, however, and in 1340, the conquest of Red Ruthenia began, marking Poland's expansion to the east. The Congress of Kraków, a vast convocation of central, eastern, and northern European rulers probably assembled to plan an anti-Turkish crusade, took place in 1364, the same year that the future Jagiellonian University, one of the oldest European universities, was founded. On 9 October 1334, Casimir III confirmed the privileges granted to Jews in 1264 by Bolesław the Pious and allowed them to settle in Poland in great numbers.
Scooter's Coffee is an American drive-through coffeehouse chain founded and headquartered in Omaha, Nebraska. As of June 2024, the chain had 800 franchises in 29 states, and was the second-largest drive-through coffee chain and the fifth-largest coffee chain in the United States.
== Selected awards == US National Academy of Inventors, Elected Fellow, 2018 T. & A. Higuchi Memorial Lectureship Award, Academy of Pharmaceutical Science and Technology, Japan, 2018 Distinguished Mentor Award, University of Utah, 2017 Doctor of Philosophy honoris causa, University of Helsinki, Finland, 2014 US National Academy of Engineering, Member, 2011 Honorary professorship, Sichuan University, China, 2007 Distinguished International Scientist Award, Japanese Biomaterials Society, 2006 Chair, Gordon Research Conference on Drug Carriers in Medicine and Biology, 2004 J. Heyrovský Honorary Medal for Merit in the Chemical Sciences, Academy of Sciences of the Czech Republic, 2003 Paul Dawson Biotechnology Award, American Association of Colleges of Pharmacy, 2001 Millennial Pharmaceutical Scientist Award, Millennial World Congress of Pharm. Sciences, 2000 Fellow of Biomaterials Science and Engineering, International Union of Societies of Biomaterials Science and Engineering, 1999 Founders Award, Controlled Release Society, 1999 Czech Learned Society, Honorary Member, 1998 Award of the Presidia of the Czechoslovak and USSR Academies of Sciences 1977 Selected publications and patents
Sources: en.wikipedia.org
== External links == Deutsch M (17 June 2016). "Guidelines for the Primary and Gender-Affirming Care of Transgender and Gender Nonbinary People" (2nd ed.). University of California, San Francisco: Center of Excellence for Transgender Health. p. 28. Bourns A (2015). "Guidelines and Protocols for Comprehensive Primary Care for Trans Clients" (PDF). Sherbourne Health Centre. Retrieved 15 August 2018. Transgender HRT Research Repository Archived 2022-09-14 at the Wayback Machine
=== H. G. Wells === Author H. G. Wells was born in Bromley on 21 September 1866, to Sarah and Joseph Wells; his father was the founder of the Bromley Cricket Club and the proprietor of a shop that sold cricket equipment. Wells spent the first 13 years of his life in Bromley. From 1874 to 1879 he attended Tomas Morley's Bromley Academy, at 74 High Street. There was a 'H. G. Wells Centre' in Masons Hill near the southern end of the High Street which housed the Bromley Labour Club (the building was demolished in 2017). In August 2005, the wall honouring Wells in Market Square was repainted; the current wall painting features a rich green background with the same Wells reference and the evolutionary sequence of Homo sapiens featured in Origin of Species by Charles Darwin, a former resident of nearby Downe Village. Wells wrote about Bromley in an early unsigned article in the Pall Mall Gazette in which he expressed satisfaction that he had been born in an earlier, more rural Bromley. A blue plaque marks Wells' birthplace in Market Square, on the wall of what is now a Primark store. A marble plaque appears above the door of 8 South Street, the location of Mrs Knott's Dame school where "Bertie", as he was called as a child, learned to read and write. H. G. Wells featured Bromley in two of his novels: The War in the Air (which refers to Bromley as Bunhill) and The New Machiavelli (in which Bromley is referred to as Bromstead). However, H. G.
== Varieties == Cattierite (CoS2), vaesite (NiS2) and hauerite (MnS2), as well as sperrylite (PtAs2) are similar in their structure and belong also to the pyrite group. Bravoite is a nickel-cobalt bearing variety of pyrite, with > 50% substitution of Ni2+ for Fe2+ within pyrite. Bravoite is not a formally recognised mineral, and is named after the Peruvian scientist Jose J. Bravo (1874–1928).
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.